AI Insight
A 2025 report published in the CDC's Morbidity and Mortality Weekly Report indicates that vaccination coverage for adolescents shows mixed results. Diphtheria toxoid and acellular pertussis (Tdap) and quadrivalent meningococcal conjugate (MenACWY) vaccines maintained approximately 90% coverage rates. However, human papillomavirus (HPV) vaccination coverage has stagnated, showing no increase for the fourth consecutive year.
Why it matters
The sustained high coverage for Tdap and MenACWY vaccines demonstrates successful immunization programs for preventing serious bacterial infections in adolescents. The plateau in HPV vaccination is concerning as it represents a missed opportunity to prevent HPV-related cancers, suggesting the need for renewed public health strategies to improve uptake of this cancer-prevention vaccine.
Understand the Science
Diphtheria toxoid and acellular pertussis (Tdap) and quadrivalent meningococcal conjugate (MenACWY) vaccination coverage for adolescents remained around 90% in 2025, and human papillomavirus (HPV) vaccination did not increase for the fourth consecutive year, according to research published in the U.S. Centers for Disease Control and Prevention Morbidity and Mortality Weekly Report.
Source: Trends reported in vaccination coverage for adolescents for 2025